1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results

BACKGROUND: In the phase 3 FLAIR study, switching to monthly injectable long-acting (LA) cabotegravir (CAB) + rilpivirine (RPV) was noninferior to continued daily oral dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) for the maintenance of virologic suppression over 96 weeks in adults with HIV-1. Key...

Descripción completa

Detalles Bibliográficos
Autores principales: Chounta, Vasiliki, Bernal, Enrique, Lombaard, Johan, Katner, Harold P, Walmsley, Sharon, Dorey, David, Spreen, William, Griffith, Sandy, Margolis, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776404/
http://dx.doi.org/10.1093/ofid/ofaa439.1221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776404/
http://dx.doi.org/10.1093/ofid/ofaa439.1221

Ejemplares similares